Company news

Adaptive Biotechnologies Corporation news in 2025

Adaptive Biotechnologies Corporation's news releases, calls and decks from 2025, newest first.

View company

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

December 14, 2025

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

December 8, 2025

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

December 6, 2025

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

December 5, 2025

Future in Tech Appoints Ed Moyle as Chief Information Security Officer

December 2, 2025

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

November 24, 2025

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

November 23, 2025

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

November 4, 2025

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

October 14, 2025

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 26, 2025

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

August 4, 2025

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

July 14, 2025

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

July 1, 2025

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

June 30, 2025

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

May 30, 2025

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

May 29, 2025

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

April 30, 2025

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

April 9, 2025

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

April 8, 2025

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

April 7, 2025

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

March 11, 2025

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

March 10, 2025

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

February 10, 2025

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

January 21, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

January 13, 2025

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

January 6, 2025

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 1, 2025

Calls in 2025

Decks in 2025